Picture of Bionexus Gene Lab logo

BGLC Bionexus Gene Lab Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeSmall CapFalling Star

Annual income statement for Bionexus Gene Lab, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2017
December 31st
2018
December 31st
2019
December 31st
2020
December 31st
2021
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUS10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue0.1080.2120.12711.413.4
Cost of Revenue
Gross Profit0.0790.0290.0561.722.19
Selling / General / Administrative Expenses
Other Operating Expenses
Total Operating Expenses0.2270.1520.40310.112.3
Operating Profit-0.1190.06-0.2761.261.04
Net Income Before Taxes-0.1190.06-0.2761.261.04
Provision for Income Taxes
Net Income After Taxes-0.1240.026-0.2461.090.752
Net Income Before Extraordinary Items
Net Income-0.1240.026-0.2461.090.752
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-0.1240.026-0.2461.090.752
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-0.0020-0.0030.0110.004
Dividends per Share

Or unlock with your email

Or unlock with your email